AGEs (advanced glycation end products) accumulate markedly in the plasma of human subjects with renal failure. We investigated the efficiency of removal of AGEs from the circulation by PD (peritoneal dialysis) and HD (haemodialysis) therapy. Free AGEs were measured by LC-MS/MS in blood plasma before dialysis, in dialysis fluid effusate after a 2-12 h dwell time in the peritoneal cavity of PD subjects, and in the HD dialysate before and after HD therapy. In clinical uraemia, the concentrations of free AGEs in blood plasma were increased up to 50-fold. For example, levels of MG-H1 (methylglyoxal-derived hydroimidazolone) were: normal controls, 110 ± 46 nM; PD subjects, 1876 ± 676 (P < 0.01); HD subjects, 5496 ± 1138 nM (P < 0.001). In PD subjects, the AGE concentration in the effusate increased with increasing dwell time, reaching a maximum at a concentration higher than that in plasma for some AGEs at 4-12 h. This may reflect AGE formation in the peritoneal cavity. In HD, AGE concentrations in HD fluid were decreased markedly from the start to the end of a dialysis session, except that levels of the methylglyoxal-derived AGEs N ε -(1-carboxyethyl)lysine and MG-H1, and of pentosidine, remained 5-fold higher than control levels.
Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis

Introduction
A key aspect of the hypothesis that advanced glycation is insidious to health is the need for degradation of AGE (advanced glycation end product)-modified proteins and renal elimination of AGEs. AGEs were found to accumulate in plasma of diabetic and non-diabetic patients with ESRD (end-stage renal disease) [1] . Kidney transplantation decreased plasma AGE levels [2] . AGEs have been detected as unidentified antigens in AGE-specific ELISAs [1, 3] and using chromatographic techniques for detection of CML (N ε -carboxymethyl-lysine) and the cross-links GOLD (glyoxal-derived lysine dimer) and MOLD (methylglyoxalderived lysine dimer) [4, 5] . Recently, however, several further complicating factors have emerged. Serum proteins of nondiabetic patients with uraemia on dialysis had abnormally high glycation -particularly in subjects with continuous ambulatory PD (peritoneal dialysis). Dialysis has, in some Key words: advanced glycation end product (AGE), haemodialysis, peritoneal dialysis, renal failure, uraemia. Abbreviations used: AGE, advanced glycation end product; CEL, N ε -(1-carboxyethyl)lysine; CML, N ε -carboxymethyl-lysine; 3DG-H, 3-deoxyglucosone-derived hydroimidazolone {N δ -[5-hydro- PD, peritoneal dialysis. 1 To whom correspondence should be addressed (e-mail thorp@essex.ac.uk).
instances, increased the serum AGE concentration in patients with uraemia [6, 7] .
Abnormalities of glycation and clearance of AGEs in uraemia may be complicated by the effect of oxidative stress induced by polymorphonuclear leucocyte activation by uraemic toxins and by interaction with the dialysis membrane in HD (haemodialysis) [8] , and by the introduction of high concentrations of glucose in dialysis fluids in PD and continuous ambulatory PD (74-214 mM). Oxidative stress decreases the cellular concentrations of glutathione and NADPH [9] . GSH is the cofactor for the detoxification of glyoxal and methylglyoxal by the glyoxalase system [10]; NADPH is the cofactor for the detoxification of 3-deoxyglucosone by 3-deoxyglucosone reductase [11] . Hence glyoxal, methylglyoxal and 3-deoxyglucosone accumulate in oxidative stress [12] and thereby AGE formation is increased. High concentrations of glucose (and α-oxoaldehydes [13] ) in dialysis fluids also increase glycation. More research is therefore required to characterize the efficiency of AGE clearance in renal dialysis protocols. We investigated the levels of AGE residues in proteins and free AGEs in blood plasma of human subjects with ESRD, each receiving one of two types of dialysis therapy, PD or HD, and normal healthy controls (Table 1 and Figure 1 ). AGEs were determined by a quantitative comprehensive screening assay by LC-MS/MS with internal standardization by stable isotope-substituted standards and calibration by reference to calibration curves produced with authentic reference AGEs [14] .
Free AGEs in plasma and dialysates in clinical dialysis
The plasma concentration of free CML was increased approx. 4-fold in PD subjects and 8-fold in HD subjects. The concentration of free CEL [N ε -(1-carboxyethyl)lysine] was increased more markedly than that of free CML, however, increasing approx. 10-fold in PD subjects and 22-fold in HD subjects. Therefore the concentrations of free CML and CEL were increased markedly in ESRD. Free hydroimidazolone AGEs were also increased markedly and severely in PD and HD subjects. G-H1 [glyoxal-derived hydroimidazolone; N δ -(5-hydro-4-imidazolon-2-yl)ornithine], MG-H1 [methylglyoxal-derived hydroimidazolone; N δ -(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine] and 3DG-H {3-deoxyglucosone-derived hydroimidazolone; N δ -[5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl]ornithine} were increased by 2-fold, 16-fold and 7-fold respectively in PD subjects, and by 4-fold, 50-fold and 10-fold respectively in HD subjects. The concentration of free pentosidine was not increased significantly in PD subjects, but was increased 5-fold in HD subjects.
In HD, AGE concentrations in the HD fluid were decreased markedly from the start to the end of a dialysis session, except that levels of the methylglyoxal-derived AGEs CEL and MG-H1, and of pentosidine, remained 5-fold higher than controls levels. In PD subjects, the AGE concentration in the effusate increased with increasing dwell time, reaching a maximum at a concentration similar to that in blood plasma by 4-12 h. The concentrations in blood plasma of CML and MG-H1 at a 2 h dwell time (Table 1 and broken line in Figures 1c and 1d) were lower than the concentrations in the peritoneal dialysate. This suggests that there is some active accumulation of free AGEs in the peritoneal cavity or that there is increased formation of AGEs in the peritoneal cavity. The latter is possible, since there are high concentrations of glucose and α-oxoaldehydes in the commercial PD fluids used.
AGE accumulation in ESRD was expected, because the normal renal excretion of AGEs was markedly decreased and the concentrations of α-oxoaldehyde precursors of AGEs, i.e. glyoxal, methylglyoxal, 3-deoxyglucosone and ribosone (a possible precursor of pentosidine), were markedly increased [15, 16] . The extraordinarily marked accumulation of free AGEs -particularly MG-H1 and 3DG-H -in PD and HD subjects may reflect increased protein glycation by the high concentrations of methylglyoxal and 3-deoxyglucosone in these subjects [15, 16] . Free AGEs probably originate mainly from the degradation of protein glycated endogenously and from AGEs absorbed from food. Lack of effective clearance of AGEs leads to their accumulation. The increased endogenous glycation in uraemia arising from increased α-oxoaldehyde levels will exacerbate this effect, particularly when glyoxalase I activity is low -as found for a uraemic subject that had an extraordinarily low glyoxalase I activity [17] . The high risk of cardiovascular complications associated with decreased glyoxalase I activity, despite controlling for other known risk factors in this subject, suggested that α-oxoaldehyde-mediated glycation may be linked to cardiovascular complications in uraemia. Inadequate clearance of free AGEs may also be linked to the increased risk of cardiovascular disease in patients with renal failure. Accumulation of free AGEs in uraemia may be a surrogate indicator of the effectiveness of dialysis therapy and a risk indicator or factor for vascular complications.
